Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200

The FDA approved Eli Lilly's once-weekly insulin injection for diabetes, adding a new product catalyst. The approval comes after Lilly shares rose 60% and approached record highs, leaving uncertainty over how much incremental upside the new indication can generate for the already strongly valued stock.